Results from recent clinical trials of antibodies that target amyloid-β (Aβ) for Alzheimer's
disease have created excitement and have been heralded as corroboration of the amyloid …

The dominant hypothesis of Alzheimer's disease (AD) aetiology, the neuropathological
guidelines for diagnosing AD and the majority of high-profile therapeutic efforts, in both …

After the CLARITY-AD clinical trial results of lecanemab were interpreted as positive, and
supporting the amyloid hypothesis, the drug received accelerated Food and Drug …

Methanol has been historically considered an exogenous product that leads only to
pathological changes in the human body when consumed. However, in normal, healthy …

Alzheimer's disease is increasingly recognized to be linked to the function and status of
metal ions, and recently, the amyloid hypothesis has been strongly intertwined with the …

Senile amyloid plaques are one of the main hallmarks of Alzheimer's disease (AD). They
correspond to insoluble deposits of amyloid-ß peptides (Aß) and are responsible for the …

Neurodegenerative diseases cause a progressive functional alteration of neuronal systems,
resulting in a state of dementia which is considered one of the most common psychiatric …

Alzheimer's Disease (AD) is a highly complex disease involving a broad range of clinical,
cellular, and biochemical manifestations that are currently not understood in combination …

Aims Inhibition of neprilysin, an enzyme degrading natriuretic and other vasoactive peptides,
is beneficial in heart failure with reduced ejection fraction (HFrEF), as shown in PARADIGM …

Aims LCZ696 (angiotensin receptor neprilysin inhibitor) is a novel drug developed for the
treatment of heart failure with reduced ejection fraction. Neprilysin is one of multiple …